CoChat

Efficacy of WeChat-Based Digital Intervention Versus Metformin in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial

Open access

Published version of a preprint

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 24 of the 46 sources its claims cite were checked for support.

Abstract

Background: The first-line treatment for polycystic ovary syndrome (PCOS) is lifestyle modification. However, it is currently unknown whether digital medicine can assist patients with PCOS in maintaining a healthy lifestyle while alleviating PCOS symptoms. Objective: This study aims to evaluate the efficacy of WeChat-based digital intervention versus metformin treatment in women with PCOS and insulin resistance. Methods: A total of 80 women with PCOS and insulin resistance were recruited from an endocrinology clinic and randomly assigned to receive either a WeChat-based digital intervention (n=40, 50%) or metformin (n=40, 50%) for 12 weeks. The WeChat-based digital intervention consisted of 3 modules; a coach assisted the patients in using the intervention. The primary outcome was the change in a homeostatic model assessment for insulin resistance. At baseline and after the 12-week intervention, anthropometric parameters, menstruation frequency, sex hormone levels, metabolic factors, and body fat distribution were measured in the clinic. Furthermore, self-assessed web-based questionnaires on diet, exercise, sleep, anxiety, and depression were obtained. Results: A total of 72 participants completed the follow-up (for a 90% follow-up rate), including 35 of 40 (88%) participants from the digital intervention group and 37 of 40 (93%) participants from the metformin group. The homeostatic model assessment for insulin resistance in the digital intervention group was significantly improved after 12 weeks of treatment with a mean change of –0.93 (95% CI –1.64 to –0.23), but no statistical difference was observed between the groups (least squares mean difference –0.20; 95% CI –0.98 to 0.58; P=.62). Both digital intervention and metformin treatment significantly improved menstruation frequency (digital intervention: P<.001; metformin: P<.001) and reduced body weight (digital intervention: P<.001; metformin: P<.001) and total fat mass (digital intervention: P<.001; metformin: P<.001). Furthermore, the digital intervention had a significant advantage over metformin in improving waist circumference (least squares mean difference –1.84; 95% CI –3.44 to –0.24; P=.03), waist-to-hip ratio (least squares mean difference –0.02; 95% CI –0.03 to 0.00; P=.03), total fat mass (least squares mean difference –1.59; 95% CI –2.88 to –0.30; P=.02), and dehydroepiandrosterone sulfate (least squares mean difference –69.73; 95% CI –129.70 to –9.75; P=.02). In terms of safety, the main adverse events were sensations of hunger in the digital intervention group (2/40, 5%) and gastrointestinal adverse events in the metformin group (12/40, 30%). Conclusions: Our data suggest that digital intervention is an effective treatment option for patients with PCOS, with an efficacy comparable to that of metformin, and that it can also alleviate the negative effects of medications and make it easier and more efficient to adhere to lifestyle treatments. WeChat-based digital interventions have the potential to provide a new path for the improvement and health of women with PCOS in China. Trial Registration: ClinicalTrials.gov NCT05386706; https://clinicaltrials.gov/study/NCT05386706

Overview

CoChat Summary

TL;DR

In a 12-week randomized trial of 80 women with PCOS and insulin resistance, a WeChat-based digital lifestyle intervention was not statistically different from metformin for improving HOMA-IR, but it produced greater reductions in waist circumference, waist-to-hip ratio, total fat mass, and DHEAS. The digital intervention also had fewer adverse events than metformin, though metformin adherence was higher.

Key findings

  • HOMA-IR improved significantly within the digital intervention group (mean change –0.93, 95% CI –1.64 to –0.23) and the metformin group (–1.07, 95% CI –2.04 to –0.09), with no significant between-group difference (least squares mean difference –0.20; 95% CI –0.98 to 0.58; P=.62).
  • Both groups significantly improved menstruation frequency (both P<.001), body weight (both P<.001), and total fat mass (both P<.001); between-group differences were not significant for menstruation frequency (P=.91) or weight (P=.63).
  • The digital intervention had a significant advantage over metformin for waist circumference (least squares mean difference –1.84 cm; 95% CI –3.44 to –0.24; P=.03), waist-to-hip ratio (–0.02; 95% CI –0.03 to 0.00; P=.03), total fat mass (–1.59 kg; 95% CI –2.88 to –0.30; P=.02), and DHEAS (–69.73 μg/dL; 95% CI –129.70 to –9.75; P=.02).
  • Adverse events were less frequent with digital intervention: sensations of hunger in 2/40 (5%) and dizziness in 1/40 (3%), versus gastrointestinal adverse events in 12/40 (30%) with metformin; metformin discontinuation due to adverse events was 5% (2/40).

Methods

  • Single-center, unblinded, 2-arm parallel randomized controlled trial with 1:1 allocation; 80 women with PCOS and HOMA-IR ≥1.8 were recruited from an endocrinology clinic at a tertiary affiliated hospital of Tongji University between June 21, 2022, and August 12, 2023.
  • Participants received either a WeChat-based digital intervention (n=40) with 3 modules and coach support or metformin 1000 mg/day (n=40) for 12 weeks; primary outcome was change in HOMA-IR, with clinical, laboratory, body composition, and questionnaire measures at baseline and 12 weeks.
  • Analysis used intention-to-treat with SPSS version 25; continuous outcomes were analyzed with ANCOVA using treatment as a fixed effect and baseline value as covariate, with P<.05 considered significant.

Limitations

  • Stated by the authors: the sample was limited to insulin-resistant PCOS and does not represent all PCOS; sex hormones were not monitored during menstruation; participants were not blinded and multiple evaluations increased type 1 error risk; no formal cost evaluation was conducted; and long-term follow-up data are lacking.
  • Evident from the text: the trial was single-center, relatively small (80 randomized, 72 followed up), and short-term (12 weeks), limiting generalizability and durability assessment.
  • Evident from the text: adherence was lower in the digital intervention group (89%, 95% CI 83%-95%) than in the metformin group (98%, 95% CI 96%-99%; P=.003), and the exclusion of perimenopausal or menopausal women was a protocol deviation not reported in the ClinicalTrials.gov registration.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2196/55883

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Overview of the components of the digital intervention.
Figure 1 Overview of the components of the digital intervention.CC BY · PubMed Central
Figure 2 Flow diagram.
Figure 2 Flow diagram.CC BY · PubMed Central

Verification

Claims the paper makes

17 Valid · 2 Not valid · 13 Not checked · 126 Own results and interpretations

74 more claims

Create a free account to see all 158 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 44
  • It may state two separate claims as one. 44

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Cited by

See all 17

Metadata

Authors
Dilimulati, D., Shao, X., Wang, L., Cai, M., Zhang, Y., Lu, J., Wang, Y., Liu, H., Kuang, M., Chen, H., Zhang, M., & Qu, S.
Affiliations
  • Tongji University (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
Zhang, Manna
Venue
Journal of Medical Internet Research
Published
2024-10-02
Volume
26
Pages
e55883
ISSN
1438-8871 (ISSN-L)
OpenAlex
W4403052591
Cited by
17
References
52
Citations by year
2026: 9 · 2025: 8
FWCI
6.66
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Medical Internet Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (82170861, 81970677, 81601269)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
Keywords
polycystic ovary syndrome, metformin, insulin resistance, lifestyle modification, menstrual frequency, body weight, waist circumference, fat mass, sex hormones, anxiety and depression, mobile health, digital medicine, HOMA-IR, body fat distribution, sleep, physical activity, diet, hirsutism
MeSH terms
Adult, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.